BioMarin Q3 2026 Revenue Jumps 32% to $1.025 Billion
BioMarin posted strong third-quarter growth driven by surging metabolic and skeletal condition drug sales, while updating full-year guidance amid order timing uncertainty.
BioMarin Pharmaceutical reported third-quarter 2026 total revenues of $1.025 billion, a 32% increase compared with the same period a year earlier, the company announced in its latest financial results.
The revenue surge was fueled by two core therapeutic areas. Sales tied to metabolic conditions climbed 44% year-over-year, while products addressing skeletal conditions contributed a 12% gain over the same stretch, underscoring broad commercial momentum across the company's rare-disease portfolio.
Read more Highland Opportunities Fund Sets $0.0385 Monthly Distribution →
Despite the strong quarterly performance, BioMarin revised its full-year 2026 guidance downward to account for uncertainty around order timing and the financial impact of two acquired in-process research and development assets. Such adjustments are common when companies absorb newly licensed or purchased pipeline programs mid-year, as the associated costs hit earnings before any revenue is generated.
The results highlight the continued commercial traction BioMarin has built in rare and ultra-rare disease markets, where pricing power and limited competition often support outsized revenue growth. Analysts will likely scrutinize the guidance revision closely to determine whether the order-timing issue reflects a one-time disruption or a broader demand signal heading into the fourth quarter.
Continue reading at All Financial Services & Investing.
